Calidi Biotherapeutics, INC Schedule 13G passive stakes

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 4.99% of Calidi Biotherapeutics, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 9.99% of Calidi Biotherapeutics, Inc. common stock as of March 31, 2026.

Lincoln Alternative Strategies LLC reports 0% beneficial ownership in Calidi Biotherapeutics, Inc., indicating a full divestment of its previous stake.

Ognian Anguelov Gavrilov has disclosed a 7.78% beneficial ownership stake in Calidi Biotherapeutics, Inc., a filing that was submitted late due to an inadvertent oversight.

Lincoln Alternative Strategies LLC has reported a 14.46% beneficial ownership stake in Calidi Biotherapeutics, Inc., holding 730,000 shares of common stock.

Armistice Capital and Steven Boyd have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Calidi Biotherapeutics, Inc.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Calidi Biotherapeutics, Inc., holding 3,359,661 shares of common stock as of March 31, 2025.